Serum keratin‐18 detects hepatic inflammation and predicts progression in compensated alcohol‐associated liver disease

Katrine Holtz Thorhauge, Maja Thiele, Sönke Detlefsen, Ditlev Nytoft Rasmussen, Stine Johansen, Bjørn Stæhr Madsen, Steen Antonsen, Lars Melholt Rasmussen, Katrine Prier Lindvig, Aleksander Krag – 19 October 2022 – Alcohol‐associated liver fibrosis accumulates over decades, driven by hepatic inflammation and cell death. We investigated the diagnostic accuracy of keratin‐18 degradation, measured using serum M30 and M65 levels, and the ActiTest for hepatic inflammatory activity in patients with compensated alcohol‐associated liver disease (ALD).

Clinical and demographic predictors of survival for fibrolamellar carcinoma patients—A patient community, registry‐based study

Amichai Berkovitz, Rachael D. Migler, Adam Qureshi, Carly Rosemore, Michael S. Torbenson, Roger Vaughan, Erin Marcotte, Sanford M. Simon – 16 October 2022 – Fibrolamellar hepatocellular carcinoma (FLC) is a rare primary liver cancer that affects primarily adolescents and young adults. It is associated with a poor overall prognosis. There is a need to better define risk factors, but small sample size has limited such studies. An FLC patient registry now provides data sufficient for statistically robust inferences.

Subscribe to